share_log

药明生物再度入选富时社会责任指数

Pharmaceutical Biotech was once again selected for the FTSE Social Responsibility Index

PR Newswire ·  Aug 17, 2022 10:30

ShanghaiAugust 17, 2022/ PR Newswire /-Wuxi Biologics (WuXi Biologics, 2269.HK), the world's leading contract research, development and production (CRDMO) company, has recently been re-listed in the FTSE Social responsibility Index (FTSE4Good Index) as one of the top 10 emerging markets components of the index.The only one in the stockEnterprises in the medical and health section.

The FTSE Social responsibility Index series, provided by FTSE Russell, the information services arm of the London Stock Exchange Group (LSEG), aims to screen out companies that meet globally recognized environmental, social and governance (ESG) standards. The index conducts independent data analysis of more than 7200 securities in 47 developed and emerging markets around the world. Among them, companies with strong ESG ratings are included in the FTSE Social responsibility Index. Wuxi Biologics's total score is significantly higher than last year, and the scores on the three major issues of environment, society and governance are all ahead of the industry average.

For a long time, Wuxi Biologics is committed to energy conservation and carbon reduction, and actively fulfill corporate social responsibility. The company has set a carbon emissions target of reducing greenhouse gas emissions by 50% by 2030 compared with 2020. By 2021, the company has achieved a significant reduction in greenhouse gas emission density for three consecutive years, and energy efficiency has continued to improve. In the first half of 2022, the company actively promoted various bases to explore the use of more renewable energy, carried out solar energy pilot projects in many bases in China, and implemented efficient and energy-saving measures in global bases, not only to improve business quality and efficiency, but also to minimize the carbon footprint. In addition, Wuxi Biologics also actively promotes the green upgrading of the supply chain, deepens supplier cooperation, and helps supply chain strategic partners seize ESG opportunities and seek sustainable development.

Dr. Chen Zhisheng, Chief Executive Officer of Wuxi Biologics, said, "being included in the FTSE Social responsibility Index again is a strong recognition of Wuxi Biologics's management and practical achievements in the environmental, social and governance areas. Wuxi Biologics always implements the sustainable development strategy, combines the company's vision and mission, and regards ESG as the core of corporate governance and the strategic cornerstone of global business development. Wuxi Biologics firmly works with partners to implement the concept of sustainable development around the world, constantly improve the level of ESG governance, actively implement corporate social responsibility, and give back to all stakeholders and even society as a whole. "

About Wuxi Biologics

Wuxi Biologics (Stock Code: 2269.HK) is a leading global contract research, development and production (CRDMO) company. Through an open and integrated biopharmaceutical capability and technology enabling platform, the company provides a full range of end-to-end services to help partners discover, develop and produce biopharmaceuticals, and realize the whole process from concept to commercial production. accelerate the global process of biopharmaceutical research and development, reduce R & D costs and benefit patients.

Wuxi Biologics has more than 10000 employees in China, the United States, Ireland, Germany and Singapore. With the professional service team composed of these employees, as well as excellent technology and insight, the company provides customers with efficient and cost-effective biopharmaceutical solutions. By the end of April 2022, Wuxi Biologics had helped customers develop and produce as many as 526 comprehensive projects, including 9 commercial production projects.

Wuxi Biologics regards Environment, Society and Governance (ESG) as an important part of business development and entrepreneurial spirit, and is committed to becoming a global ESG leader in biopharmaceutical CRDMO, such as leading the industry in the application of greener new generation biopharmaceutical technologies and energy. The company has established an ESG committee led by the CEO to fully implement the ESG strategy and implement the commitment to sustainable development. For more information, please visit.

For more information, please contact

Media relations

PR@wuxibiologics.com

ESG

Esg@wuxibiologics.com

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment